Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups

Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano